Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TVG canine leishmaniasis vaccine
- Development stage
- Preclinical
- Lead developer
- TVG
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
TVG's canine leishmaniasis vaccine is an experimental veterinary vaccine candidate developed by The Vaccine Group (TVG). It utilizes a proprietary herpesvirus-based viral vector platform designed to deliver and express specific *Leishmania* antigens within the host. This approach aims to stimulate a robust and protective cell-mediated immune response, which is essential for controlling the intracellular protozoan parasite *Leishmania infantum*, the primary cause of canine leishmaniasis. By leveraging the immunogenic properties of the herpesvirus vector, the vaccine is intended to provide long-lasting immunity against this serious zoonotic disease. The program is currently in the preclinical stage of development.
- Other names
- Leishmania vaccine (canine)TVG Leishmania vaccinecanine leishmaniasis vaccine-TVG-Leishmania antigen-herpesvirus-based viral-vector vaccine-Canine leishmaniasis
Beyond the preview
Go deeper on TVG canine leishmaniasis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TVG canine leishmaniasis vaccine.